Revolution Medicines, Inc. (NASDAQ:RVMDW – Get Free Report) was the target of a significant growth in short interest during the month of June. As of June 30th, there was short interest totaling 3,115 shares, a growth of 127.5% from the June 15th total of 1,369 shares. Based on an average daily volume of 95,598 shares, the short-interest ratio is presently 0.0 days.
Revolution Medicines Trading Down 7.3%
NASDAQ:RVMDW opened at $8.41 on Friday. Revolution Medicines has a one year low of $0.16 and a one year high of $10.12. The stock has a 50-day simple moving average of $7.02 and a 200 day simple moving average of $4.07.
Revolution Medicines Company Profile
Revolution Medicines (NASDAQ:RVMDW) is a clinical-stage oncology company focused on discovering and developing small-molecule therapies that target the RAS signaling pathway. The company’s scientific approach centers on designing molecules that selectively inhibit mutant RAS proteins and key regulators of RAS-driven cancers, with the goal of addressing tumor types that have historically been resistant to targeted therapies.
Revolution Medicines has advanced multiple pipeline candidates into clinical trials, including RMC-4630, a selective SHP2 inhibitor, and RMC-6236, an oral pan-RAS inhibitor designed to block signaling from multiple RAS mutants.
Featured Stories
- Five stocks we like better than Revolution Medicines
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
